Building a roadmap for developing combination therapies for Alzheimer’s disease
Year: 2015
Type: article
Abstract: Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases. A growing number of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease. A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Critical Path Institute and the Alzheimer's Association addressed challenges in designing clinical trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.
Authors: Daniel Perry, Reisa Sperling, Russell Katz, Donald Berry, David Dilts, Debra Hanna, Stephen Salloway, John Q Trojanowski, Chas Bountra, Michael Krams, Johan Luthman, Steven Potkin, Val Gribkoff, Robert Temple, Yaning Wang, Maria C Carrillo, Diane Stephenson, Heather Snyder, Enchi Liu, Tony Ware, John McKew, F Owen Fields, Lisa J Bain, Cynthia Bens
Institutions: Alliance for Aging Research, Brigham and Women's Hospital, Harvard University, United States Food and Drug Administration, The University of Texas MD Anderson Cancer Center, Oregon Health & Science University, Critical Path Institute, Brown University, Butler Hospital, University of Pennsylvania, University of Oxford, Eisai (United States), Eisai (Japan), University of California, Irvine, Elan Pharmaceuticals, Inc. (Ireland), Alzheimer's Association, Eli Lilly (United States), National Institutes of Health, Pfizer (United States)
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2011334740